Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...

UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...

A first clinical study suggests allogeneic CD19-targeted CAR-T cell therapy can safely induce durable remission in patients ...

Editing CAR T cells to produce inflammatory cytokines helps them enter solid tumors and promote cancer killing.

FDA-approved updates for Breyanzi and Abecma reduce patient monitoring and eliminate REMS, enhancing access to CAR T-cell therapies. Labeling changes reflect increased regulatory confidence in the ...

While the use of radiation bridging therapy (BT) in chimeric antigen receptor (CAR) T-cell therapy for blood cancer is expanding, plenty of unanswered questions remain on topics such as ideal timing ...

A study published in the Journal of Clinical Oncology confirms that one of the first Food and Drug Administration-approved CAR-T cell therapies offers long-term survival and potential cures for adult ...

FDA approval criteria primarily dictate the sequencing of multiple myeloma therapies, often restricting bispecific antibodies to later treatment lines. Institutional practices vary in using CAR T-cell ...

CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has revolutionized how physicians treat cancer, especially blood cancers. “These patients can be cured ...

Chimeric antigen receptor (CAR) T-cell therapies have transformed cancer and autoimmune disease treatment. Modified CAR proteins equip T cells with the ability to identify and eliminate cancer cells ...

Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.